Home medical equipment company AdaptHealth Corp (NASDAQ:AHCO) revealed on Friday that it has entered into a definitive agreement to acquire the Patient Care Solutions (PCS) business from McKesson Corporation.
Subject to customary closing conditions, the acquisition is expected to close in December 2019.
AdaptHealth stated that the total investment, including restructuring costs until the business is fully integrated on AdaptHealth's platform in the latter half of 2020, is anticipated to be approximately USD30m.
PCS provides wound care supplies, ostomy supplies, urological supplies, incontinence supplies, diabetic care supplies and breast pumps directly to patients across the US. The company said it maintains extensive national relationships with physicians, medical facilities and customers, currently serving all 50 states. For the trailing 12 months ended 31 October 2019, it generated net revenues of about USD134m.
Under the terms of the agreement, AdaptHealth will sign a supply and distribution agreement with McKesson Corporation with respect to PCS's HME service lines.
Fusion Antibodies secures multi-target humanisation contract with global pharmaceutical client
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return